Research programme: hyperlipidaemia therapies - Handok Inc.

Drug Profile

Research programme: hyperlipidaemia therapies - Handok Inc.

Alternative Names: HL 4130

Latest Information Update: 03 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Handok Pharmaceuticals
  • Developer Handok Inc
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 03 Oct 2013 Discontinued - Preclinical for Hyperlipidaemia in South Korea (unspecified route)
  • 01 Jul 2013 Handok Pharmaceuticals is now called Handok Inc.
  • 22 Jun 2011 Research programme: hyperlipidaemia therapies - Handok Pharmaceuticals is available for partnering as of 22 Jun 2011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top